Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 4.58
AVEO's Cash to Debt is ranked higher than
71% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. AVEO: 4.58 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: No Debt
Current: 4.58

Equity to Asset 0.45
AVEO's Equity to Asset is ranked higher than
60% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AVEO: 0.45 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.79
Current: 0.45

-3.21
0.79
F-Score: 3
Z-Score: -6.71
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -354.50
AVEO's Operating margin (%) is ranked higher than
61% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. AVEO: -354.50 )
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -354.5

-8035.89
20.59
Net-margin (%) -368.03
AVEO's Net-margin (%) is ranked higher than
61% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. AVEO: -368.03 )
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -368.03

-8277.57
18.59
ROE (%) -87.05
AVEO's ROE (%) is ranked higher than
59% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. AVEO: -87.05 )
AVEO' s 10-Year ROE (%) Range
Min: -113.33   Max: 20.76
Current: -87.05

-113.33
20.76
ROA (%) -44.70
AVEO's ROA (%) is ranked higher than
63% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. AVEO: -44.70 )
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -44.7

-88.25
13.74
ROC (Joel Greenblatt) (%) -420.13
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. AVEO: -420.13 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -420.13

-1669.78
678.74
Revenue Growth (%) -74.20
AVEO's Revenue Growth (%) is ranked higher than
56% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AVEO: -74.20 )
AVEO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -67.6
Current: -74.2

EBITDA Growth (%) -2.30
AVEO's EBITDA Growth (%) is ranked higher than
79% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. AVEO: -2.30 )
AVEO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -2.3
Current: -2.3

EPS Growth (%) -3.00
AVEO's EPS Growth (%) is ranked higher than
81% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AVEO: -3.00 )
AVEO' s 10-Year EPS Growth (%) Range
Min: 0   Max: -3
Current: -3

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AVEO Guru Trades in Q3 2013

Jim Simons 1,308,753 sh (+7.51%)
Seth Klarman 3,829,350 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 160,000 sh (-70.37%)
» More
Q4 2013

AVEO Guru Trades in Q4 2013

Paul Tudor Jones 109,101 sh (New)
Chuck Royce 218,583 sh (+36.61%)
Seth Klarman 3,829,350 sh (unchged)
Jim Simons 1,299,070 sh (-0.74%)
» More
Q1 2014

AVEO Guru Trades in Q1 2014

Steven Cohen 500,000 sh (New)
Seth Klarman 3,829,350 sh (unchged)
Chuck Royce Sold Out
Jim Simons 1,275,453 sh (-1.82%)
Paul Tudor Jones 106,701 sh (-2.2%)
» More
Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Paul Tudor Jones 106,701 sh (unchged)
Seth Klarman 3,829,350 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.02 - $1.72 $ 1.04-19%49076
Seth Klarman 2013-06-30 Reduce -21.9%0.26%$2.34 - $8.27 $ 1.04-76%3829350
George Soros 2011-12-31 Sold Out 0.0031%$14.53 - $17.35 $ 1.04-88%0
Seth Klarman 2011-09-30 Add 12.79%0.29%$15.12 - $20.77 $ 1.04-94%5000000
George Soros 2011-09-30 Reduce -92.8%0.04%$15.12 - $20.77 $ 1.04-94%11600
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.20
AVEO's P/B is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. AVEO: 1.20 )
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 1.2

0.87
22.16
P/S 2.90
AVEO's P/S is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. AVEO: 2.90 )
AVEO' s 10-Year P/S Range
Min: 0.64   Max: 111.5
Current: 2.9

0.64
111.5
EV-to-EBIT -0.04
AVEO's EV-to-EBIT is ranked higher than
50% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AVEO: -0.04 )
AVEO' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 16.9
Current: -0.04

6.3
16.9
Current Ratio 2.59
AVEO's Current Ratio is ranked higher than
67% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. AVEO: 2.59 )
AVEO' s 10-Year Current Ratio Range
Min: 1.55   Max: 9.47
Current: 2.59

1.55
9.47
Quick Ratio 2.59
AVEO's Quick Ratio is ranked higher than
69% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. AVEO: 2.59 )
AVEO' s 10-Year Quick Ratio Range
Min: 1.55   Max: 9.47
Current: 2.59

1.55
9.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.90
AVEO's Price/Net Cash is ranked higher than
89% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. AVEO: 6.90 )
AVEO' s 10-Year Price/Net Cash Range
Min: 1.75   Max: 24.76
Current: 6.9

1.75
24.76
Price/Net Current Asset Value 6.50
AVEO's Price/Net Current Asset Value is ranked higher than
88% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. AVEO: 6.50 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.62   Max: 24.22
Current: 6.5

1.62
24.22
Price/Tangible Book 1.20
AVEO's Price/Tangible Book is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. AVEO: 1.20 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 1.2

1.2
14.66
Price/Median PS Value 0.60
AVEO's Price/Median PS Value is ranked higher than
94% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. AVEO: 0.60 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 21.69
Current: 0.6

0.15
21.69
Earnings Yield (Greenblatt) 3204.80
AVEO's Earnings Yield (Greenblatt) is ranked higher than
100% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. AVEO: 3204.80 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.9   Max: 3204.8
Current: 3204.8

5.9
3204.8
Forward Rate of Return (Yacktman) -250.80
AVEO's Forward Rate of Return (Yacktman) is ranked higher than
54% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. AVEO: -250.80 )
AVEO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.5   Max: 1.3
Current: -250.8

-0.5
1.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany
AVEO Pharmaceuticals Inc. was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The company is seeking to develop multiple new drugs that target important mechanisms known or believed to be involved in cancer. The company's product pipeline includes its drug candidate, tivozanib, a small molecule oral cancer drug designed to prevent tumor growth by inhibiting angiogenesis, as well as monoclonal antibodies against HGF and ErbB3. Tivozanib was partnered with Astellas Pharma Inc. It also demonstrated a statistically significant improvement in PFS with a median PFS of 12.7 months compared to a median PFS of 9.1 months for Nexavar in the pre-specified subpopulation of patients who received no prior systemic anti-cancer therapy for metastatic disease—a subpopulation that comprised approximately 70% of the total study population. In addition to the TIVO-1 study, the company is evaluating tivozanib in multiple phases 1 and phases 2 clinical trials including its BATON (Biomarker Assessment of Tivozanib in ONcology) program, a series of clinical trials assessing tivozanib biomarkers in solid tumors. The company has acquired exclusive rights to develop and commercialize tivozanib worldwide outside of Asia pursuant to a license agreement it entered into with Kirin Brewery Co. Ltd in 2006. Under the license agreement, it obtained an exclusive license to research, develop, manufacture and commercialize tivozanib, pharmaceutical compositions thereof and associated biomarkers for the diagnosis, prevention and treatment of any and all human diseases and conditions outside of Asia. KHK has retained all rights to tivozanib in Asia. The company's proprietary Human Response Platform was designed to overcome many of the limitations of traditional approaches to modeling human cancer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK